{"filing":{"accession_number":"0001104659-26-080562","cik":"0000872589","ticker":"REGN","company_name":"REGENERON PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"tm2619682d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465926080562/tm2619682d1_8k.htm"},"events":[{"id":16097,"run_id":14364,"accession_number":"0001104659-26-080562","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"This Item 2.02 disclosure provides preliminary financial results for Q2 2026, specifically flagging an expected acquired IPR\u0026D charge of approximately $127 million that will negatively impact both GAAP and non-GAAP net income per diluted share by approximately $1.00. While the full earnings release is not attached, the disclosure of preliminary quarterly financial results and their expected impact on per-share metrics is characteristic of an earnings-related disclosure under Item 2.02, even though the company notes results have not been finalized.","company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":14075,"accession_number":"0001104659-26-080562","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"This Item 2.02 disclosure provides preliminary financial results for Q2 2026, specifically flagging an expected acquired IPR\u0026D charge of approximately $127 million that will negatively impact both GAAP and non-GAAP net income per diluted share by approximately $1.00. While the full earnings release is not attached, the disclosure of preliminary quarterly financial results and their expected impact on per-share metrics is characteristic of an earnings-related disclosure under Item 2.02, even though the company notes results have not been finalized.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T11:01:44.553914+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14075,"accession_number":"0001104659-26-080562","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"This Item 2.02 disclosure provides preliminary financial results for Q2 2026, specifically flagging an expected acquired IPR\u0026D charge of approximately $127 million that will negatively impact both GAAP and non-GAAP net income per diluted share by approximately $1.00. While the full earnings release is not attached, the disclosure of preliminary quarterly financial results and their expected impact on per-share metrics is characteristic of an earnings-related disclosure under Item 2.02, even though the company notes results have not been finalized.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-06T11:01:44.553914+00:00","company_name":"REGENERON PHARMACEUTICALS, INC.","ticker":"REGN","filing_date":"2026-07-06"}]}